Effect of angiotensin receptor blockade and anti hypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction:: a randomised trial

被引:250
作者
Solomon, Scott D.
Janardhanan, Rajesh
Verma, Anil
Bourgoon, Mikhail
Daley, William L.
Dos Purkayastha
Lacourciere, Yves
Hippler, Stephen E.
Fields, Harold
Naqvi, Tasneem Z.
Mulvagh, Sharon L.
Arnold, Malcolm O.
Thomas, James D.
Zile, Michael R.
Aurigemma, Gerard P.
机构
[1] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA
[2] Univ Massachusetts, Med Ctr, Worcester, MA USA
[3] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[4] Mayo Clin, Rochester, MN USA
[5] Med Univ S Carolina, Charleston, SC 29425 USA
[6] Dept Vet Affairs Med Ctr, Charleston, SC USA
[7] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[8] London Hlth Sci Ctr, London, ON, Canada
[9] Ctr Hosp Univ Laval, Ste Foy, PQ, Canada
[10] Clin Res Ctr, OSF Med Grp, Peoria, IL USA
[11] Village Family Practice Res, Houston, TX USA
[12] Novartis Pharmaceut, E Hanover, NJ USA
关键词
D O I
10.1016/S0140-6736(07)60980-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Diastolic dysfunction might represent an important pathophysiological intermediate between hypertension and heart failure. Our aim was to determine whether inhibitors of the renin-angiotensin-aldosterone system, which can reduce ventricular hypertrophy and myocardial fibrosis, can improve diastolic function to a greater extent than can other antihypertensive agents. Methods Patients with hypertension and evidence of diastolic dysfunction were randomly assigned to receive either the angiotensin receptor blocker valsartan (titrated to 320 mg once daily) or matched placebo. Patients in both groups also received concomitant antihypertensive agents that did not inhibit the renin-angiotensin system to reach targets of under 135 mm Hg systolic blood pressure and under 80 mm Hg diastolic blood pressure. The primary endpoint was change in diastolic relaxation velocity between baseline and 38 weeks as determined by tissue doppler imaging. Analyses were done by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00170924. Findings 186 patients were randomly assigned to receive valsartan; 198 were randomly assigned to receive placebo. 43 patients were lost to follow-up or discontinued the assigned intervention. Over 38 weeks, there was a 12.8 (SD 17.2)/7.1 (9.9) mm, Hg reduction in blood pressure in the valsartan group and a 9.7 (17.0)/5.5 (10.2) mm Hg reduction in the placebo group. The difference in blood pressure reduction between the two groups was not significant. Diastolic relaxation velocity increased by 0.60 (SD 1.4) cm/s from baseline in the valsartan group (p < 0.0001) and 0.44 (1.4) cm/s from baseline in the placebo group (p < 0.0001) by week 38. However, there was no significant difference in the change in diastolic relaxation velocity between the groups (p=0.29). Interpretation Lowering blood pressure improves diastolic function irrespective of the type of antihypertensive agent used.
引用
收藏
页码:2079 / 2087
页数:9
相关论文
共 38 条
[1]   Diastolic dysfunction precedes myocardial hypertrophy in the development of hypertension [J].
Aeschbacher, BC ;
Hutter, D ;
Fuhrer, J ;
Weidmann, P ;
Delacrétaz, E ;
Allemann, Y .
AMERICAN JOURNAL OF HYPERTENSION, 2001, 14 (02) :106-113
[2]   Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction >=40% treated with diuretics plus angiotensin-converting enzyme inhibitors [J].
Aronow, WS ;
Ahn, C ;
Kronzon, I .
AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 (02) :207-209
[3]   Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: The Cardiovascular Health Study [J].
Aurigemma, GP ;
Gottdiener, JS ;
Shemanski, L ;
Gardin, J ;
Kitzman, D .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (04) :1042-1048
[4]   Diastolic heart failure [J].
Maurer, MS ;
Packer, M ;
Burkhoff, D .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (11) :1143-1143
[5]   Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease [J].
Brilla, CG ;
Funck, RC ;
Rupp, H .
CIRCULATION, 2000, 102 (12) :1388-1393
[6]   Human SERCA2a levels correlate inversely with age in senescent human myocardium [J].
Cain, BS ;
Meldrum, DR ;
Joo, KS ;
Wang, JF ;
Meng, XZ ;
Cleveland, JC ;
Banerjee, A ;
Harken, AH .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (02) :458-467
[7]   The perindopril in elderly people with chronic heart failure (PEP-CHF) study [J].
Cleland, John G. F. ;
Tendera, Michal ;
Adamus, Jerzy ;
Freemantle, Nick ;
Polonski, Lech ;
Taylor, Jacqueline .
EUROPEAN HEART JOURNAL, 2006, 27 (19) :2338-2345
[8]   A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure [J].
Cohn, JN ;
Tognoni, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (23) :1667-1675
[9]   REVERSAL OF LEFT-VENTRICULAR HYPERTROPHY IN HYPERTENSIVE PATIENTS - A METAANALYSIS OF 109 TREATMENT STUDIES [J].
DAHLOF, B ;
PENNERT, K ;
HANSSON, L .
AMERICAN JOURNAL OF HYPERTENSION, 1992, 5 (02) :95-110
[10]   Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol -: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial [J].
Devereux, RB ;
Dahlöf, B ;
Gerdts, E ;
Boman, K ;
Nieminen, MS ;
Papademetriou, V ;
Rokkedal, J ;
Harris, KE ;
Edelman, JM ;
Wachtell, K .
CIRCULATION, 2004, 110 (11) :1456-1462